ArticleBMC cancer2024

Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma.

Thao D Pham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.